Cellectis S.A.

Paris Stock Exchange ALCLS.PA

Cellectis S.A. Debt to Equity Ratio for the year ending December 31, 2023: 1.00

Cellectis S.A. Debt to Equity Ratio is 1.00 for the year ending December 31, 2023, a 43.00% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Cellectis S.A. Debt to Equity Ratio for the year ending December 31, 2022 was 0.70, a 52.01% change year over year.
Cellectis S.A. Debt to Equity Ratio for the year ending December 31, 2021 was 0.46, a 14.39% change year over year.
Cellectis S.A. Debt to Equity Ratio for the year ending December 31, 2020 was 0.40, a 167.33% change year over year.
Cellectis S.A. Debt to Equity Ratio for the year ending December 31, 2019 was 0.15, a 4,476.97% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Paris Stock Exchange: ALCLS.PA

Cellectis S.A.

CEO	Dr. Andre Choulika Ph.D.
IPO Date	Feb. 7, 2007
Location	France
Headquarters	8, rue de la Croix Jarry
Employees	216
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Key trends

Past 5 years